Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.59 |
| ▸ | CASP1 | P29466 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | ECE1 | P42892 | 1/20 | 0.55 |
| ▸ | CTSK | P43235 | 3/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624700 | 1.00 | FOLH1 (0.59) | FOLH1CASP1HTTMMEECE1 | |
| SCHEMBL2921260 | 1.00 | FOLH1 (0.59) | FOLH1CASP1HTTMMEECE1 | |
| SCHEMBL30902878 | 0.95 | MME (0.56) | FOLH1CASP1HTTMMEECE1 | |
| SCHEMBL10565196 | 0.93 | FOLH1 (0.58) | FOLH1CASP1HTTMMEECE1 | |
| SCHEMBL4910765 | 0.93 | FOLH1 (0.58) | FOLH1CASP1HTTMMEECE1 | |
| SCHEMBL3624634 | 0.92 | FOLH1 (0.55) | FOLH1CASP1MMEECE1CTSK | |
| SCHEMBL3624630 | 0.92 | FOLH1 (0.55) | FOLH1CASP1MMEECE1CTSK | |
| SCHEMBL21232384 | 0.92 | FOLH1 (0.52) | FOLH1CASP1MMEECE1CTSK | |
| SCHEMBL21221151 | 0.92 | FOLH1 (0.52) | FOLH1CASP1MMEECE1CTSK | |
| SCHEMBL7286347 | 0.92 | FOLH1 (0.55) | FOLH1CASP1MMEECE1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458188-B2 | Efficient peptide couplings and their use in the synthesis and isolation of a cyclopenta (G) quinazoline trisodium salt | BTG INTERNATIONAL LIMITED (GB) | 2016-10-04 | — | — | US | claimed |
| EP-2655398-B1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | BTG INT LTD (GB) | 2016-08-24 | — | — | EP | claimed |
| US-20130345423-A1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | Onyx Pharmaceutical, Inc. (US) | 2013-12-26 | — | — | US | claimed |
| EP-2655398-A2 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | Onyx Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | claimed |
| WO-2012087888-A2 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | ONYX PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | claimed |
| EP-0624599-B1 | Derivatives of mono (6-amino-desoxy)cyclodextrin substituted in position 6 with an alpha aminoacid group, process of their preparation and applications | OREAL (FR) | 1997-07-30 | — | — | EP | claimed |
| US-12629423-B2 | Olfactory delivery scaffolds using antisense oligonucleotides and methods for making and using same | OLFERA CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260062447-A1 | COMPOUNDS | UNIV SOUTHAMPTON (GB) | 2026-03-05 | — | — | US | disclosed |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4648799-A1 | LIGAND-DRUG CONJUGATES | Sun Pharma Advanced Research Company Ltd (IN) | 2025-11-19 | — | — | EP | disclosed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250269038-A1 | Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using Same | OLFERA CORPORATION | 2025-08-28 | — | — | US | disclosed |
| WO-1988001650-A1 | ENZYMATIC PROCESS | CELLTECH LIMITED (GB) | 1988-03-10 | — | — | WO | disclosed |
| EP-0189305-A2 | Peptide derivatives | ICI AMERICAS INC. (US) | 1986-07-30 | — | — | EP | disclosed |
| US-4591459-A | Intermediates for 6-(aminoacyloxymethyl) penicillanic acid 1,1-dioxides | PFIZER INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4503040-A | 6-(Aminoacyloxymethyl)penicillanic acid 1,1-dioxides as beta-lactamase inhibitors | PFIZER INC. (US) | 1985-03-05 | — | — | US | disclosed |
| EP-0052296-B1 | GLUTAMINE DERIVATIVES USABLE FOR CURING IMMUNE DISEASES, METHODS FOR THEIR PREPARATION AND COMPOSITIONS COMPRISING SAID DERIVATIVES | MITSUBISHI KASEI CORPORATION (JP) | 1984-06-27 | — | — | EP | disclosed |
| US-4439448-A | IMMUNOMODULATING ACTIVITY | MITSUBISHI CHEMICAL INDUSTRIES LTD. (JP) | 1984-03-27 | — | — | US | disclosed |
| EP-0052296-A1 | Glutamine derivatives usable for curing immune diseases, methods for their preparation and compositions comprising said derivatives | MITSUBISHI KASEI CORPORATION (JP) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269038-A1 | Olfactory Delivery Scaffolds Using Antisense Oligonucleotides and Methods for Making and Using Same | OR51E2, OR10J3, GAP43 | FOLH1 2912/4885CASP1 2135/4885HTT 152/4885 |
| US-12629423-B2 | Olfactory delivery scaffolds using antisense oligonucleotides and methods for making and using same | OR10J3, OR51E2, TAS2R43 | FOLH1 4180/4885CASP1 1200/4885HTT 793/4885 |
| US-20260062447-A1 | COMPOUNDS | VHL, HIF1A, HYOU1 | FOLH1 1894/4885CASP1 1704/4885HTT 2794/4885 |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | FOLH1 368/4885CASP1 3852/4885HTT 1719/4885 |
| US-20130345423-A1 | EFFICIENT PEPTIDE COUPLINGS AND THEIR USE IN THE SYNTHESIS AND ISOLATION OF A CYCLOPENTA (G) QUINAZOLINE TRISODIUM SALT | GLUL, QPCT, GLS | FOLH1 94/4885CASP1 4032/4885HTT 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.